Clinical Outcomes Associated With the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease

Degenerative Disc Disease Clinical Trial

— ViviGen  

Official title:

Clinical Outcomes Associated With the Use of ViviGen® in Conjunction With Posterolateral Fusion for the Treatment of Lumbar Degenerative Disc Disease

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03733626
• Other study ID #: 2018-158
• Status: Active, not recruiting
• Phase: N/A
• Start date: March 19, 2019
• Est. completion date: June 2024

Study information

• Verified date: February 2024
• Source: William Beaumont Hospitals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to perform a prospective, randomized, controlled clinical trial to compare radiographic fusion rates and patient reported outcomes, including pain and function preoperatively and postoperatively, using Depuy ViviGen® Cellular Bone Matrix mixed with cortical/cancellous allograft in conjunction with an approved Depuy Synthes pedicle screw system compared to autograft mixed with cortical/cancellous allograft in conjunction with the same DePuy Synthes pedicle screw system used for a one or two - level posterolateral lumbar fusion.

Description:

This is a prospective randomized, non-blinded, controlled study. Patients with a diagnosis of degenerative disc disease and/or up to grade I spondylolisthesis and planning to undergo a one or two-level instrumented posterolateral lumbar fusion surgery between L1-S1 will be screened. If eligible and the subject meets all the inclusion criteria and none of the exclusion criteria, the subject will be approached about study participation by the surgeon. If the subject agrees to participate, the consent process will be initiated by the study coordinator. Once the patient has been consented; data including medical history, neurological exam, patient questionnaires (visual analogue pain score (VAS), Oswestry low-back disability questionnaire (ODI), short form health survey (SF-36)) will be collected. Randomization will occur once a surgery date has been scheduled so the appropriate instrumentation can be boarded accordingly. A randomization envelope will reveal randomization treatment group. The envelopes will be generated in a 1:1 fashion and be randomly allocated to an assigned study identification number.

Subjects will be randomized to either: 1) treatment arm where the investigator will use an FDA approved/cleared DePuy Synthes spinal pedicle screw system with ViviGen® Cellular Bone Matrix mixed with cortical/cancellous allograft or the 2) control arm where the investigator use the same DePuy Synthes spinal pedicle screw system with local autologous bone graft mixed with cortical/cancellous allograft. Both treatment groups represent standard of care lumbar fusion surgeries using two types of bone graft options to create the arthrodesis as comparators.

Once the lumbar fusion surgery has taken place as planned; data will be collected regarding the surgery performed, including operative time, amount of bone graft used, spinal system used, length of hospital stay, and adverse events/complications.

Study subjects will be followed up at 6-weeks, 3-months, 6-months, and 12-months postoperatively at the private practice or clinic. During these routine (standard of care) postoperative visits, subjects will complete questionnaires (VAS, ODI, SF-36, patient satisfaction) and have neurological exam (lumbar spine exam, see appendix 1) completed by the investigator. Adverse events related to device and/or procedure will be evaluated as each postoperative visit. Anteroposterior (AP) and lateral x-rays will be performed at all visits with flexion and extension x-rays added at baseline, 3-months, 6-months, and 12-months. A CT scan of the lumbar spine will be performed during the 12-month postoperative time frame at the Beaumont-Royal Oak Imaging Center. Radiographic analysis will be performed and evaluated for fusion status as evidenced by bony bridging, presence of radiolucency, and development of pseudoarthrosis at each follow-up visit.

This study design reflects the current standard of care for lumbar spinal stenosis, degenerative disc disease and lumbar degenerative spondylolisthesis. Lumbar fusion surgery using pedicle screw fixation with autograft and allograft bone grafting options is treatment of choice after conservative (non-surgical) therapies have been implemented and failed.

Addendum:

1. In order to protect the well-being of patients and in compliance with the current state mandated shelter in place order, follow-up visits will be completed via telephone visit by the study coordinator when possible. This includes patient reported outcomes and adverse event reporting. Some parts of the study visit may not be completed over the phone such as lumbar x-rays, neuro exam, and CT scan (at 12-months postop); these missing (or scheduled at a later date) protocol specific items will be noted as a protocol deviation with the reason being due to COVID-19.

2. If a televisit is not possible, the visit may be rescheduled at a later date. Therefore, out of window and missing visits will be recorded as protocol deviations with the reason being due to COVID-19.

3. Subject follow-up visits will be rescheduled in the office once the acute phase of the pandemic has subsided if the study visit is not substantially out of window.

4. Subject enrollment is on hold until the acute phase of the pandemic has subsided but screening will continue.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 46
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. =18 years of age

2. Able to provide consent

3. Is undergoing standard of care one or two-level instrumented posterolateral fusion at the level between L1-S1

4. Has diagnosis of spinal stenosis, degenerative disc disease and/or up to Grade 1 spondylolisthesis

5. Requires decompression at intended fusion level (multi-level decompression allowed L1-S1)

6. Has failed 6-weeks or more of conservative, non-operative treatment

7. Has back and/or radicular lumbar symptoms with ODI score of = 30 preoperatively.

Exclusion Criteria:

1. Any prior lumbar fusion surgery

2. Requires fusion of more than two levels

3. Requires an interbody fusion based on relevant diagnoses and factors (such as foraminal stenosis, degree of spondylolisthesis, spinal deformity, disc space collapse, and subject's age) as determined by investigator

4. BMI > 40

5. Active systemic infection or infection at operative site

6. History of an osteoporotic fracture and/or vertebral body fracture

7. Is currently being treated with chemotherapy, radiation, immunosuppression or chronic steroid therapy

8. History of osteoporosis, osteopenia, or osteomalacia that would contraindicate spinal surgery

9. Psychological or physical condition in the opinion of the investigator that would interfere with subject self-assessments

10. History of neurological condition in the opinion of the investigator that may affect lumbar function and pain assessments

11. Subjects with a history of cancer must be disease free for at least 3 years

12. Pregnant, or plans on becoming pregnant

Related Conditions & MeSH terms

• Degenerative Disc Disease
• Degenerative Spondylolisthesis
• Intervertebral Disc Degeneration
• Lumbar Disc Disease
• Lumbar Radiculopathy
• Lumbar Spinal Stenosis
• Lumbar Spondylolisthesis
• Radiculopathy
• Spinal Diseases
• Spinal Stenosis
• Spondylolisthesis

Intervention

Combination Product:
• ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system
ViviGen® is manufactured by LifeNet Health. ViviGen® Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10 and will be used with the FDA approved DePuy Synthes Spinal pedicle screw system for fusion.
• Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system
Patient's own bone harvested during spinal surgery will be used with the FDA approved DePuy Synthes spinal pedicle screw system to create the fusion.

Locations

Country	Name	City	State
United States	William Beaumont Hospital	Royal Oak	Michigan

Sponsors (2)

Lead Sponsor	Collaborator
William Beaumont Hospitals	DePuy Synthes

Country where clinical trial is conducted

United States, 

References & Publications (8)

Betz RR. Limitations of autograft and allograft: new synthetic solutions. Orthopedics. 2002 May;25(5 Suppl):s561-70. doi: 10.3928/0147-7447-20020502-04. — View Citation

Boden SD. Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine (Phila Pa 1976). 2002 Aug 15;27(16 Suppl 1):S26-31. doi: 10.1097/00007632-200208151-00007. — View Citation

DeCoster TA, Gehlert RJ, Mikola EA, Pirela-Cruz MA. Management of posttraumatic segmental bone defects. J Am Acad Orthop Surg. 2004 Jan-Feb;12(1):28-38. doi: 10.5435/00124635-200401000-00005. — View Citation

DePuy Synthes. https://www.depuysynthes.com/hcp/spine/products/qs/vivigen-cellular-bone-matrix. Copyright DePuy Synthes 2014-2017. DePuy Synthes Biomaterials Division 1302 Wrights Lane East, West Chester, Pennsylvania 19380.

Gazdag AR, Lane JM, Glaser D, Forster RA. Alternatives to Autogenous Bone Graft: Efficacy and Indications. J Am Acad Orthop Surg. 1995 Jan;3(1):1-8. doi: 10.5435/00124635-199501000-00001. — View Citation

Kang J, An H, Hilibrand A, Yoon ST, Kavanagh E, Boden S. Grafton and local bone have comparable outcomes to iliac crest bone in instrumented single-level lumbar fusions. Spine (Phila Pa 1976). 2012 May 20;37(12):1083-91. doi: 10.1097/BRS.0b013e31823ed817. — View Citation

Kim DH, Rhim R, Li L, Martha J, Swaim BH, Banco RJ, Jenis LG, Tromanhauser SG. Prospective study of iliac crest bone graft harvest site pain and morbidity. Spine J. 2009 Nov;9(11):886-92. doi: 10.1016/j.spinee.2009.05.006. Epub 2009 Jun 18. — View Citation

Vaccaro AR, Stubbs HA, Block JE. Demineralized bone matrix composite grafting for posterolateral spinal fusion. Orthopedics. 2007 Jul;30(7):567-70. doi: 10.3928/01477447-20070701-06. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of successful Lumbar Fusion measured radiographically	Count of participants with successful lumbar bone fusion as measured by CT scan and flexion/extension x-rays at 12-months as evidenced by the following three criteria: bony bridging, no presence of radiolucency and no development of pseudoarthrosis at the treated lumbar level	12 months postoperative
Secondary	Visual Analog Scale for Pain	Equal to or greater than a 2-point decrease in patient reported outcomes as measured by Visual Analog Scale for pain (0-10 point scale, 0 = no pain and 10 = severe amount of pain) from baseline to 12-months.	12 months postoperative
Secondary	Change in Oswestry Disability Index for Pain and Function	Equal to or greater than 15-point decrease in patient reported outcomes as measured by Oswestry Disability Index (0-100 point scale, 0 = least amount of disability, 100 = most severe disability) from baseline to 12-months.	12 months postoperative
Secondary	Change in Short Form Health Survey-36 for Quality of Life	Equal to or greater than 15-point increase in patient reported outcomes as measured by SF-36 (0-100 point scale, 0 = low favorable health state and 100 = most favorable health state) from baseline to 12-months.	12 months postoperative
Secondary	Neurological Deficit per Lumbar Spine Neurological Exam	Count of participants with new or worsening neurological (lumbar motor and sensory) deficit as evaluated by lumbar spine neurological exam from baseline through 12 months.	12 months postoperative
Secondary	Count of participants with revision surgery by month 12	Count of participants with revision surgery by month 12	12 months postoperative
Secondary	Count of participants developing pseudoarthrosis by month 12	Count of participants developing pseudoarthrosis by month 12	12 months postoperative